{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"71.350","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"298,735,566","primaryexch":"香港交易所","ric":"2162.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BLPPZP6","am":"175.07","iv":"","ew_strike":"","as":"70.300","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"70.200","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"27.050","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"Bo Chen","underlying_ric":"2162.HK","hi52":"80.000","issuer_name":"康諾亞生物醫藥科技有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"68.400","mkt_cap":"21.00","f_aum_hkd":null,"ew_sub_per_to":"","ls":"70.300","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.700","aum":"","issued_shares_class_B":null,"vo":"2.50","secondary_listing_flag":false,"listing_date":"2021年7月8日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"康諾亞生物醫藥科技有限公司 - B","nm_s":"康諾亞－Ｂ","sym":"2162","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.050","strike_price":"","summary":"康諾亞生物醫藥科技有限公司是一家生物科技公司，專注於自主發現及開發自體免疫及腫瘤治療領域的創新生物療法的公司。該公司還專注於醫藥產品的研究和開發。該公司的主要產品有CM310、CM326、CM313和CM383，可治療各種成人、青少年及兒童I型免疫性疾病，例如中重度特應性皮炎、中重度哮喘、慢性鼻賨炎伴鼻息肉、過敏性鼻炎，亦可能可以治療慢性阻塞性肺疾病。該公司還建立了涵蓋生物藥開發的關鍵功能的全面一體化平臺。該公司主要在中國國內和海外市場開展業務。","op":"69.500","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港灣仔<br/>皇后大道東248號<br/>大新金融中心<br/>40樓","pc":"-0.99","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"71.000","isin":"KYG5252B1023","moneyness":""}},"qid":"1759074096804"}
